Lv51
910 积分 2024-05-13 加入
Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer
1小时前
已完结
Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis
12天前
已完结
HARMONi: A New Tune in EGFRm NSCLC?
18天前
已关闭
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
18天前
已完结
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
18天前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
19天前
已关闭
Past, present and future of drug conjugates for cancer therapy
21天前
已完结
In vivo CAR engineering for immunotherapy. Nat Rev Immunol (2025)
29天前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
1个月前
已完结
皖公网安备34019202002308
